Ignite Creation Date:
2025-12-25 @ 4:11 AM
Ignite Modification Date:
2026-03-06 @ 6:39 PM
Study NCT ID:
NCT03017820
Status:
RECRUITING
Last Update Posted:
2025-10-08
First Post:
2017-01-09
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Sponsor:
Mayo Clinic
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | B-Cell Non-Hodgkin Lymphoma | View |
| None | Histiocytic and Dendritic Cell Neoplasm | View |
| None | Myelodysplastic Syndrome | View |
| None | Previously Treated Myelodysplastic Syndrome | View |
| None | Recurrent Adult Acute Myeloid Leukemia | View |
| None | Recurrent Anaplastic Large Cell Lymphoma | View |
| None | Recurrent Angioimmunoblastic T-Cell Lymphoma | View |
| None | Recurrent Mycosis Fungoides | View |
| None | Recurrent Plasma Cell Myeloma | View |
| None | Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | View |
| None | Recurrent T-Cell Non-Hodgkin Lymphoma | View |
| None | Refractory Acute Myeloid Leukemia | View |
| None | Refractory Anaplastic Large Cell Lymphoma | View |
| None | Refractory Angioimmunoblastic T-Cell Lymphoma | View |
| None | Refractory Mycosis Fungoides | View |
| None | Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified | View |
| None | Refractory Plasma Cell Myeloma | View |
| None | Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | View |
| None | Refractory T-Cell Non-Hodgkin Lymphoma | View |
Keywords: